Wedbush analyst, David Nierengarten, is cautious on Ironwood Pharmaceuticals (NASDAQ: IRWD) as operating leverage remains elusive. No change to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results February 19, 2016 9:30 AM BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'February 19, 2016 7:50 AM Leerink Partners Remains Sidelined After Ironwood Pharma's (IRWD) 4Q February 19, 2016 7:22 AM Ironwood Pharma (IRWD) Tops Q4 EPS by 7cFebruary 18, 2016 4:07 PM Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor UpdateFebruary 18, 2016 4:05 PM